Stockreport
BioMarin discontinues dosing in certain Voxzogo trials after safety concern [Yahoo! Finance]
Last biomarin pharmaceutical inc. earnings: 4/29 04:01 pm
Check Earnings Report
US:NASDAQ Investor Relations: investors.biomarin.com
Syndrome, SHOX-deficiency and Aggrecan (ACAN)-deficiency after safety events in two investigator-led trials. According to a US Securities and Exchange Commission (SEC) listing, filed on 16 March, several patients suffered slipped capital femoral epiphysis (SCFE) in two ongoing investigator-sponsored trials. This event is characterised by the head of the femur slipping backwards off the growth plate. BioMarin said that SCFE events have not been observed in its other Phase II trials in these same conditions. The company added that no cases have been observed in the more than 5,000 infants and children who have received Voxzogo for achondroplasia in clinical studies or post-marketing surveillance. There have similarly been no observed cases in BioMarin's clinical trials for hypochondroplasia, an indication in which BioMarin is focusing for the drugs next approval. The Phase II CANOPY trials of Voxzogo in children with Noonan syndrome (NCT06668805), as well as those living with id
[Read more]
| IMPACT SNAPSHOT | EVENT TIME: | BMRN | ||||
|---|---|---|---|---|---|---|
|
Last Price
|
Price Change
|
Price Change %
|
Volume Shares
|
Max Up
|
Max Down
|
Volume Ratio
%
|
Performance comparison
Updated
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| LAST PRICE | ||
| VWAP | ||
|
High:
|
MAX UP |
High:
|
|
Low:
|
MAX DOWN |
Low:
|
|
%
|
POST NEWS RANGE |
%
|
|
|
PRICE CHANGE |
|
|
|
PRICE CHANGE PERCENTAGE |
|
|
|
S&P 500 (SPX) |
|
|
%
|
VOLUME RATIO |
%
|
| VOLUME (SHARES) | ||
| TICKS | ||
|
|
AVG SHARES PER TRADE |
|
Don't Miss Out On The Next BIG Stock Move
EVENT DAY
Event Day Chart will not be displayed beyond 90-day period of the event
PERFORMANCE SINCE EVENT
TIME AND VELOCITY ANALYSIS
Be the first to know
Opt in for alerts from News Quantifed
Opt-in for
BMRN alerts
BMRN alerts
from News Quantified
Movers & Shakers
The biggest gainers and losers and WHY it moved
BMRN alerts
High impacting BioMarin Pharmaceutical Inc. news events
Weekly update
A roundup of the hottest topics
BMRN
NEWS
NEWS
- BioMarin Pharmaceutical (BMRN) was downgraded by <a style="font-weight:bold" href="https://weissratings.com/">Weiss Ratings</a> from "hold (c-)" to "sell (d+)".[MarketBeat]
- BioMarin Pharmaceutical's Rare Disease Portfolio Supplemented By Amicus Acquisition Makes A Buy [Seeking Alpha][Seeking Alpha]
- BioMarin Pharmaceutical (BMRN) was upgraded by <a style="font-weight:bold" href="https://weissratings.com/">Weiss Ratings</a> from "sell (d+)" to "hold (c-)".[MarketBeat]
- Here is Why BioMarin (BMRN) is Projected to Rally [Yahoo! Finance][Yahoo! Finance]
- BioMarin Pharmaceutical Inc. (BMRN) Rated Overweight at Wells Fargo Despite Voxzogo Phase 2 Study Discontinuations [Yahoo! Finance][Yahoo! Finance]
- More
BMRN
SEC Filings
SEC Filings
- 3/26/26 - Form SCHEDULE
- 3/19/26 - Form 4
- 3/19/26 - Form 4
- BMRN's page on the SEC website
- More